Lichen planus–like eruptions: An emerging side effect of tumor necrosis factor-α antagonists

Asarch, Adam; Gottlieb, Alice B.; Liu, Jin; Masterpol, Katherine Szyfelbein; Scheinman, Pamela L.; Stadecker, Miguel J.; Massarotti, Elena; Bush, Michelle

doi:10.1016/j.jaad.2008.09.032

Cited by 172 publications

(117 citation statements)

References 33 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…No clear event precipitating TNF-a blockers cutaneous eruptions has yet been identified (2,4,(19)(20)(21)(22); on the contrary, the triggers of our cases were seemingly manifest (topical imiquimodin the presence of a population of neoplastic KCs, both factors conjunctively prompting release of IFN-a), with the reactions always being limited to areas of application and sparing any distant sites.…”

Section: Discussioncontrasting

confidence: 61%

“…To date, it has not been understood why only a minority of patients developed any of these anti-TNF-a-induced reactions in general, and any specific clinico-pathological variants in particular. It seems likely that the common setting of systemic TNF-a inhibition always plays a key role, whereas currently unresolved differences in signaling cascades would account for small rates of affected patients as well as observed variances in clinicopathological outcomes (4,21,23).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Exaggerated Imiquimod Application Site Reactions in the Context of Systemic Tumor Necrosis Factor-Alpha Inhibition: More Than a Coincidental Occurrence?

Saggini

Saraceno

Chimenti

2011

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Topical imiquimod and tumor necrosis factor (TNF)-α inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively. While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-α blockers to elicit cutaneous inflammatory reactions has only recently been recognized. We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association. To date, no relation has ever been suggested between TNF-α inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod. We believe that this subject deserves further analysis; meanwhile, increased attention should be drawn to the possibility of this adverse interaction, as simultaneous treatment with TNF-α blockers and imiquimod is becoming increasingly frequent in daily practice.

show abstract

Section: Discussioncontrasting

confidence: 61%

Section: Discussionmentioning

confidence: 99%

Exaggerated Imiquimod Application Site Reactions in the Context of Systemic Tumor Necrosis Factor-Alpha Inhibition: More Than a Coincidental Occurrence?

Saggini

Saraceno

Chimenti

2011

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…Bunlar içerisinde etanersept ile oluşan kutanöz yan etkiler; enjeksiyon yeri reaksiyonları, ekzematöz deri lezyonları, lupus eritematozus, eritema multiforme, deri enfeksiyonları, vasküler lezyonlar, deri kanserleri ve likenoid erüpsiyonlar olarak sayılabi-lir. [2][3][4][5] Likenoid erüpsiyonlar, aslında çok sayıda ilaca bağlı olarak görülebilmektedir. Özellikle altın tuzları, β blokerler, antimalaryaller, tiyazid diüretik-ler, furosemid, spirinolakton ve penisilamin en sık neden olan ilaçların başında gelmektedir.…”

Section: Olgu Sunumuunclassified

“…[1][2][3][4][5] TNF-α inhibitörleri ile tedaviye başlanması ve likenoid erüpsiyonların görülmesi arasındaki süre, genellikle üç hafta ile 16 ay arasında değişmekle birlikte, en sık tedaviye başlandıktan sonraki ilk iki ayda izlenmektedir. 3 Hastaların çoğunluğunda tedavinin kesilmesini gerektirmeden erüpsiyon iyileş-miştir. 2 Bizim hastamızda da etanersept ile tedaviye başlandıktan dört ay sonra gövde yan ve arka yüzde likenoid erüpsiyon izlenmiş ve etanersept kullanımı kesilmeden topikal tedavi ile iyileşme sağlanmıştır.…”

Section: Olgu Sunumuunclassified

Etanercept Treatment Induced Lichenoid Eruption: Case Report

İyidal¹,

Çokbankir²,

Kılıç³

2016

Turkiye Klinikleri J Dermatol

View full text Add to dashboard Cite

“…Lichen Planopilaris: Lichenoid drug reactions are a wellestablished adverse reaction to TNF-α inhibitors [48]. A rare but reported subcategory includes TNF-α inhibitor induced lichen planopilaris (LPP).…”

Section: Clinical Subtypes Of Alopecia Seen During Treatment With Tnfmentioning

confidence: 99%

Hair Loss Induced by Tumor Necrosis Factor Alpha Inhibitors

Tosti¹

2014

J Clin Investig Dermatol

View full text Add to dashboard Cite

Background: Alopecia is a possible adverse reaction to Tumor Necrosis Factor alpha (TNF-α) inhibitors. This side effect has become more recognized in recent years through FDA postmarketing surveillance and it description in case reports/case series. Objective:We review the literature and summarize the pathogenesis, clinical presentation, prognosis, and management strategies for TNF-α inhibitor induced alopecia. Methods:We performed a Medline search from January 1998 until August 2013 to identify all cases of alopecia during anti-TNF-α therapy described in the literature. We also reviewed FDA postmarketing data and clinical trials.Results: There were 62 cases of hair loss occurring during therapy with TNF-α inhibitors that we identified during our literature search. The causes of hair loss included alopecia areata, psoriatic alopecia, lichen planopilaris, drug-induced lupus erythematosus, androgenetic alopecia, and telogen effluvium. Alopecia was also a mentioned side effect in three clinical trials and in FDA postmarketing surveillance.Limitations: There are few controlled trials directly studying TNF-α inhibitor induced alopecia and most of our understanding of this clinical condition comes from anecdotal experience.Conclusions: TNF-α inhibitors can cause different types of hair loss including severe alopecia areata and scarring alopecia.

show abstract

Lichen planus–like eruptions: An emerging side effect of tumor necrosis factor-α antagonists

Cited by 172 publications

References 33 publications

Exaggerated Imiquimod Application Site Reactions in the Context of Systemic Tumor Necrosis Factor-Alpha Inhibition: More Than a Coincidental Occurrence?

Exaggerated Imiquimod Application Site Reactions in the Context of Systemic Tumor Necrosis Factor-Alpha Inhibition: More Than a Coincidental Occurrence?

Etanercept Treatment Induced Lichenoid Eruption: Case Report

Hair Loss Induced by Tumor Necrosis Factor Alpha Inhibitors

Contact Info

Product

Resources

About